A23. CAR-T and radiopharmaceuticals: legal, ethical and regulatory issues impacting the new wave of medical treatments
Tracks
Medical Devices Regulation Summit
Tuesday, June 3, 2025 |
4:30 PM - 5:30 PM |
Parkside 1 |
Chair & Speakers
Jonathan Kelp
Partner
MinterEllison
CAR-T and radiopharmaceuticals: legal, ethical and regulatory issues impacting the new wave of medical treatments
Biography
Rebecca Pereira
Special Counsel
MinterEllison
A23: CAR-T and radiopharmaceuticals: legal, ethical and regulatory issues impacting the new wave of medical treatments
Abstract
This panel session will explore the unique considerations that arise from the new wave of cancer treatments – CAR-T cell therapy and radiopharmaceuticals – including IP protection (and infringement) issues, the TGA’s regulatory framework, the interaction with human tissue and radioactivity regulations, and supply chain / distribution complications.
Biography
Rebecca is a specialised intellectual property lawyer with 17 years' advisory and litigious experience. She has a focus on complex IP disputes, particularly in the life sciences sector. Rebecca has considerable litigation (trial and appellate) experience, particularly in relation to multi-jurisdictional IP disputes, interlocutory disputes, the analysis of patent infringement and validity, and in the preparation of evidence with expert witnesses.
Rebecca has acted in numerous advisory and contentious trade mark and consumer law disputes. She is also an experienced commercial lawyer with front-end experience drafting and negotiating commercialisation agreements, IP licences and confidentiality agreements.
In addition to her legal qualifications, Rebecca has a Bachelor of Science and a Masters in Intellectual Property Law. She is a member of the Victorian and Trans-National Committees of IPSANZ and is a member of AIPPI.
Rebecca was recognised in the 2025 and 2026 editions of ‘Best Lawyers in Australia’ for Intellectual Property Law and was named as a Rising Star in Managing Intellectual Property’s IP Stars in 2019 and 2022-2024.
